Legacy Foundation HBO2

Clinical Trial Title A Pilot Study Comparing Acute Post-Radiation Hyperbaric Oxygen (HBO2) versus Trental and Vitamin E for Breast Cancer Patients Who Have Recently Completed Radiation Therapy as Part of Their Treatment Course
Trial Status Closed to Enrollment
Start Date 07/23/2019
Location Doctors & Locations
Trial Type Cancer - Adult Oncology
Specific Condition Breast cancer
Eligibility Criteria

Inclusion Criteria

  • Patient is currently undergoing treatment for breast cancer and is on one of two pathways:
  •     Pathway 1 involves lumpectomy with radiation therapy, recurrence years later, mastectomy and tissue expander with further radiation therapy
  •     Pathway 2 involves mastectomy and tissue expander, 6 weeks of radiation therapy, and an implant in 6 months
  • Undergone mastectomy with expander or implant reconstruction > 2 weeks before starting radiation therapy
  • Completed chest wall irradiation in the past 3 days
  • Willing to stop herbal medications as directed by provider
  • Willing to stop daily use of supplemental vitamin E (Multivitamin with vitamin E component is acceptable, vitamin E cream is also acceptable)
  • Willing to have photographs of chest area taken for research purposes only

Exclusion Criteria

  • Have final implant placed < 2 weeks before start of radiation therapy
  • Plan to place final impacts < 4 months from the completion of radiation therapy, if tissue expanders are intact during radiation therapy
  • Radiation completed more than 3 days prior to study start
  • Unwilling or unable to stop oral supplemental Vitamin E

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number Central IRB
Principal Investigator Enoch Huang, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org